Shire clinical trials

Acquired by Takeda, Jan 8, 2019 · source ↗

The registry lists 351 studies whose lead sponsor is Shire. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 23, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 351. List all 351 → · All Takeda studies →

• Gaucher Disease Outcome Survey (GOS)RecruitingNCT03291223

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• A Study of Replagal in Children and Adults With Fabry Disease in IndiaRecruitingNCT05067868Phase 4

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• Registry for Participants With Short Bowel SyndromeActive, not recruitingNCT01990040

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• A Study of Intrathecal SHP611 in Children With Metachromatic LeukodystrophyCompletedNCT03771898Phase 2

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic LeukodystrophyCompletedNCT01887938Phase 1/2

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)CompletedNCT04085172Phase 4

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of AgeCompletedNCT02455622Phase 4

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behavior When Using NATPARACompletedNCT05556629

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese ParticipantsCompletedNCT04497883Phase 1

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or IICompletedNCT04130191

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult ParticipantsTerminatedNCT04131556Phase 1

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094CompletedNCT02412787Phase 2/3

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)CompletedNCT02954458Phase 3

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 StudyCompletedNCT02949362Phase 3

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• FIRAZYR General Drug Use-Results Survey (Japan)CompletedNCT04057131

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)TerminatedNCT03245840Phase 3

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is AchievedCompletedNCT02605837Phase 3

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)CompletedNCT02736409Phase 3

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)CompletedNCT01034969

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• Hunter Outcome Survey (HOS)CompletedNCT03292887

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• A European Post-Authorisation Observational Study (Registry) of Patients With Chronic Adrenal Insufficiency (AI)TerminatedNCT01661387

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)CompletedNCT03283085Phase 3

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• A Study of Replagal in Treatment-naïve Adults With Fabry DiseaseTerminatedNCT04840667Phase 3

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-InhibitorCompletedNCT04444895Phase 3

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• A Study of SHP655 (rADAMTS13) in Sickle Cell DiseaseCompletedNCT03997760Phase 1

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• A Study of VPRIV in Participants With Gaucher Disease Previously Treated With Other Enzyme Replacement Therapies or Substrate Reduction TherapiesTerminatedNCT04094181

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701)CompletedNCT03582449

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• Drug Use Study With Intuniv® in European CountriesCompletedNCT05870605

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and AdultsNo longer availableNCT04583007

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE)CompletedNCT03324880Phase 4

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in IndiaCompletedNCT04429984

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North AmericaCompletedNCT03845400

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell TransplantsCompletedNCT02927067Phase 3

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)CompletedNCT03922308Phase 2

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic HypoparathyroidismWithdrawnNCT03878953Phase 3

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• Safety and Efficacy Study of rhPTH(1-84) in Subjects With HypoparathyroidismTerminatedNCT03364738Phase 3

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult ParticipantsCompletedNCT04465396Phase 1

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)CompletedNCT04180163Phase 3

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in ChildrenCompletedNCT04070326Phase 3

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302CompletedNCT03268811Phase 3

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)CompletedNCT02386839Phase 2

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)TerminatedNCT03627091Phase 3

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHDCompletedNCT00500071Phase 4

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral SupportCompletedNCT02980666Phase 3

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher DiseaseCompletedNCT02574286Phase 4

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative ColitisCompletedNCT03290781Phase 3

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• Drug Use Study With VYVANSE® in Australia for Binge Eating DisorderCompletedNCT04866043

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• Retrospective, Observational Chart Review Study Conducted in Poland to Document the Management and Clinical Outcome of CUVITRU and HYQVIA in Pediatric Participants (< 18 Years) With Primary Immunodeficiency (PID)CompletedNCT04636502

  Sponsor listed in the registry: Shire · First submitted after Shire became part of Takeda

• Fabry Outcome Survey (FOS)CompletedNCT03289065

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda

• Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or CidofovirCompletedNCT02931539Phase 3

  Sponsor listed in the registry: Shire · First submitted before Shire became part of Takeda